辛伐他汀对血脂异常人群糖代谢的影响

发布时间：2018-06-28 17:12

本文选题：血脂异常 + 糖化血红蛋白　；参考：《广东医学》2017年10期

【摘要】：目的探讨辛伐他汀对血脂异常人群代谢的影响。方法将120例血脂异常的患者分为糖耐量正常(NGT)、空腹血糖受损(IFG)及糖耐量异常(IGT)3组,每组40例。给予辛伐他汀20 mg/d,于服药前、服药4、12和24周分别测定血糖、糖化血红蛋白、胰岛素、总胆固醇、三酰甘油、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、尿酸、肝肾功能、血压、体质指数。结果用药4周后,患者总胆固醇、低密度脂蛋白胆固醇明显降低(t=2.274,P=0.035),高密度脂蛋白胆固醇明显升高(t=2.395,P=0.024),继续服药至24周,总胆固醇、低密度脂蛋白胆固醇进一步下降,所有患者均达到治疗目标。空腹血糖、餐后2 h血糖及糖化血红蛋白等3个指标,组间差异有统计学意义(P0.05)。两两比较并结合主要数据来看:各指标随时间的变化幅度较小,和基线水平相比均不显著;但餐后2 h血糖,IGT组明显高于NGT、IFG两组(P0.05);与基线相比,3组患者在治疗后4、12及24周转氨酶均无显著升高。3组患者治疗后体质指数、血压均较治疗前有所下降,但差异无统计学意义。结论辛伐他汀治疗后明显降低非糖尿病患者的总胆固醇和低密度脂蛋白胆固醇水平、升高高密度脂蛋白胆固醇水平,糖代谢各项指标变化不明显。
[Abstract]:Objective to investigate the effects of simvastatin on metabolism of dyslipidemia people. Methods 120 patients with dyslipidemia were divided into 3 groups: glucose tolerance Liang Zhengchang (NGT), impaired fasting blood glucose (IFG) and glucose tolerance abnormality (IGT), 40 cases in each group. 20 mg/d of simvastatin was given. Before taking the medicine, the blood glucose, glycated hemoglobin, insulin, and total gallbladder were measured in 4,12 and 24 weeks respectively. Sterol, three acyl glycerol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, uric acid, liver and kidney function, blood pressure, body mass index. Results after 4 weeks, the total cholesterol, low density lipoprotein cholesterol (t=2.274, P=0.035), high density lipoprotein cholesterol (t=2.395, P=0.024), continue to take medicine to 24 weeks, total bile solid Alcohol, low density lipoprotein cholesterol further decreased, all the patients reached the target of treatment. Fasting blood glucose, postprandial 2 h blood sugar and glycated hemoglobin, and other 3 indicators, there was a significant difference between groups (P0.05). 22 comparison and combined with the main data that the index changes with time is smaller, but not significant compared with the baseline level; After 2 h blood glucose, group IGT was significantly higher than that of NGT and IFG two (P0.05). Compared with baseline, the 3 groups had no significant increase in body mass index after treatment in 4,12 and 24 weeks after treatment, and the blood pressure was lower than before treatment, but the difference was not statistically significant. Conclusion the total cholesterol of non diabetic patients was significantly reduced after the treatment of simvastatin. And low density lipoprotein cholesterol level, high density lipoprotein cholesterol level and glucose metabolism index were not changed significantly.
【作者单位】：广州市第十二人民医院内二科;中山大学附属第三医院内分泌科;
【基金】：广东省医学科研基金立项课题(编号:A2014596)
【分类号】：R589.2

【相似文献】